Novavax (NVAX) to Release Quarterly Earnings on Thursday

Novavax (NASDAQ:NVAX) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $90.2580 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Novavax Stock Up 0.5%

Shares of NVAX opened at $8.69 on Thursday. The firm has a market cap of $1.41 billion, a P/E ratio of 4.85 and a beta of 2.58. Novavax has a 12 month low of $5.01 and a 12 month high of $10.64. The stock’s 50 day moving average is $7.90 and its two-hundred day moving average is $7.94. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93.

Institutional Investors Weigh In On Novavax

A number of large investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in Novavax during the third quarter worth approximately $33,000. State of Wyoming purchased a new stake in Novavax in the 2nd quarter valued at $52,000. Danske Bank A S acquired a new stake in shares of Novavax in the 3rd quarter worth $64,000. Dimensional Fund Advisors LP acquired a new stake in shares of Novavax in the 4th quarter worth $75,000. Finally, Williams Jones Wealth Management LLC. purchased a new position in shares of Novavax during the 4th quarter worth $77,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVAX. B. Riley Financial reissued a “buy” rating and issued a $16.00 price target (down previously from $18.00) on shares of Novavax in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novavax in a report on Monday, December 29th. Wall Street Zen cut shares of Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. BTIG Research restated a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, January 20th. Finally, HC Wainwright lifted their price objective on Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, Novavax presently has an average rating of “Hold” and an average target price of $11.25.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.